The estimated Net Worth of Capital, L.P.Altiva Managem... is at least $32.8 millió dollars as of 9 September 2019. Capital Managem owns over 72,023 units of Progenics Pharmaceuticals stock worth over $32,848,105 and over the last 5 years Capital sold PGNX stock worth over $0.
Capital has made over 3 trades of the Progenics Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital bought 72,023 units of PGNX stock worth $359,395 on 9 September 2019.
The largest trade Capital's ever made was buying 521,038 units of Progenics Pharmaceuticals stock on 3 September 2019 worth over $2,318,619. On average, Capital trades about 265,706 units every 6 days since 2019. As of 9 September 2019 Capital still owns at least 8,011,733 units of Progenics Pharmaceuticals stock.
You can see the complete history of Capital Managem stock trades at the bottom of the page.
Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch és Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
Progenics Pharmaceuticals executives and other stock owners filed with the SEC include: